Difference between revisions of "Acute myeloid leukemia trial demographics"
Jump to navigation
Jump to search
m |
m |
||
| Line 65: | Line 65: | ||
|} | |} | ||
''<sup>a</sup>Age is not reported separately by arm. | ''<sup>a</sup>Age is not reported separately by arm. | ||
| + | |||
| + | '''This work is supported in part by [https://reporter.nih.gov/search/bweQKIeIwk-kOtL_oHSGSw/project-details/10705015 NCI U24 CA265879].''' | ||
| + | |||
[[Category:General reference pages]] | [[Category:General reference pages]] | ||
Revision as of 16:40, 12 September 2023
| Study | Arm | Age, median (range) | Sex (%M/%F) | Race | Performance Status |
|---|---|---|---|---|---|
| Wiernik et al. 1992 | 7+3d (standard-dose) | 55 (NR) | 57/43 | NR | ECOG 0-1: 86% |
| Wiernik et al. 1992 | 7+3i | 56 (NR) | 56/44 | NR | ECOG 0-1: 87% |
| ECOG E1900 | 7+3d (standard-dose) | 47 (17-60) | 52/48 | NR | NR |
| ECOG E1900 | 7+3d (high-dose) | 48 (18-60) | 50/50 | NR | NR |
| HOVON 43 AML/SAKK 30/01 | 7+3d (standard-dose) | 67 (60-79) | 57/43 | NR | ECOG 0-1: 88% |
| HOVON 43 AML/SAKK 30/01 | 7+3d (high-dose) | 67 (60-83) | 53/47 | NR | ECOG 0-1: 88% |
| ADcomparison | 7+3d (standard-dose) | 43 (15-60)a | 48/52 | NR | KPS 90-100%: 80% |
| ADcomparison | 7+3d (high-dose) | 43 (15-60)a | 60/40 | NR | KPS 90-100%: 82.5% |
aAge is not reported separately by arm.
This work is supported in part by NCI U24 CA265879.